Evidence map›Paper›PMID 38831354›Full record

ArticleCancer imaging : the official publication of the International Cancer Imaging Society2024

[

Youcai Li, Yin Zhang, Zhihua Guo, Peng Hou, Jie Lv, Miao Ke, Shaoyu Liu, Siwen Li, Weiqiang Yin, Jianxing He and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer imaging : the official publication of the International Cancer Imaging Society, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. [European journal of nuclear medicine and molecular imaging · 2026
    Article
  3. [European journal of nuclear medicine and molecular imaging · 2026
    Article
  4. Review
  5. Article
  6. Fibroblast Activation Protein Inhibitor (FAPI)-Based Theranostics.Pharmaceuticals (Basel, Switzerland) · 2025
    Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Youcai Li *Department of Nuclear Medicine, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510000, China.
Yin Zhang *Nanfang PET Center, Southern Medical University Nanfang Hospital, Guangzhou, Guangdong Province, China.
Zhihua GuoDepartment of Thoracic Surgery, Guangzhou Institute of Respiratory Health & China State Key Laboratory of Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, National Clinical Research Center for Respiratory Disease, Guangzhou, China.
Peng HouDepartment of Nuclear Medicine, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510000, China.
Jie LvDepartment of Nuclear Medicine, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510000, China.
Miao KeDepartment of Nuclear Medicine, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510000, China.
Shaoyu LiuDepartment of Nuclear Medicine, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510000, China.
Siwen LiGuangzhou Medical University, Guangzhou, China.
Weiqiang YinDepartment of Thoracic Surgery, Guangzhou Institute of Respiratory Health & China State Key Laboratory of Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, National Clinical Research Center for Respiratory Disease, Guangzhou, China.
Jianxing HeDepartment of Thoracic Surgery, Guangzhou Institute of Respiratory Health & China State Key Laboratory of Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, National Clinical Research Center for Respiratory Disease, Guangzhou, China.
Xinlu WangDepartment of Nuclear Medicine, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510000, China. 71lu@163.com.ORCID http://orcid.org/0000-0003-1997-5687

Funding

Guangdong Medical Science and Technology Research Funding A2023233the National Natural Science Foundation of China (No. 82001879the Science and Technology Program of Guangzhou 202102010252the Science and Technology Program of Guangzhou 202201020558the Science and Technology Program of Guangzhou 2024A03J1160
6 · The paper itself

Abstract

backgroundThis study investigates the value of fluorine 18 ([

methodsFrom November 2021 to October 2022, 53 patients with stage I-IIIA NSCLC who underwent radical resection were prospectively included. [

resultsIn 53 patients (median age, 64 years, range: 31-76 years), the specificity of [

conclusionIn patients with stage I-IIIA NSCLC, [

trial registrationThe Chinese Clinical Trial Registry: ChiCTR2100044944 (Registered: 1 April 2021, https://www.chictr.org.cn/showprojEN.html?proj=123995 ).

Indexed as

Carcinoma, Non-Small-Cell LungFluorodeoxyglucose F18Lung NeoplasmsLymphatic MetastasisNeoplasm StagingPositron Emission Tomography Computed TomographyRadiopharmaceuticalsAdultAgedFemaleHumansLymph NodesMaleMiddle AgedProspective StudiesFluorodeoxyglucose F18RadiopharmaceuticalsFAPIFDGLymph node metastasesNon-small cell lung cancer

Identifiers

PMID38831354
PMCPMC11145785

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.